Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 253
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00003627 | Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx | ||
| NCT03169075 | QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program | ||
| NCT02444390 | Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor | ||
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | ||
| NCT02363751 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24) | ||
| NCT02539537 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | ||
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | ||
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | ||
| NCT05625087 | Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib | ||
| NCT03667417 | Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation | ||
| NCT00190385 | Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis | ||
| NCT00667069 | Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer | ||
| NCT03722680 | Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. | ||
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | ||
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma | ||
| NCT06867705 | Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only | ||
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | ||
| NCT06653777 | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells | ||
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | ||
| NCT00287846 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | ||
| NCT03320161 | A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project | ||
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | ||
| NCT05443087 | TARGETed Therapy Drug MONITOring in DIGestive Oncology | ||
| NCT00003607 | Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer | ||
| NCT02754011 | Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative | ||
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types | ||
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma | ||
| NCT06027632 | Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer | ||
| NCT00003852 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | ||
| NCT04985266 | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer | ||
| NCT02363049 | Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | ||
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists | ||
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients | ||
| NCT00004205 | Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer | ||
| NCT01780220 | Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery | ||
| NCT06446882 | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer | ||
| NCT03878342 | Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast | ||
| NCT05297617 | Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk | ||
| NCT00006050 | Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | ||
| NCT04246606 | Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer | ||
| NCT00053911 | Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | ||
| NCT03870919 | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients | ||
| NCT01443065 | MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma | ||
| NCT05296746 | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | ||
| NCT01564056 | Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment | ||
| NCT00002883 | Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus | ||
| NCT01415674 | Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients | ||
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | ||
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | ||
| NCT06606730 | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer |
